Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
Crispr Therapeutics (CRSP) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Crispr Therapeutics (CRSP) has started a Phase 1 trial called “A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias.” The study tests a new in vivo gene edit to lower stubborn blood lipids, a large market tied to cardiovascular and metabolic disease risk.
The treatment, CTX310, is an experimental drug given by intravenous infusion. It uses a lipid nanoparticle system to deliver Crispr components inside the body, with the goal of switching off the ANGPTL3 gene and improving dangerous cholesterol and triglyceride levels.
The trial is interventional, with one treatment group and no placebo or randomization. It is open label, so both doctors and patients know they are receiving CTX310, and the main aim is to test safety and tolerability, not yet to prove full clinical benefit.
The study is listed as recruiting, meaning patient dosing is underway or about to begin. Key dates include initial submission on March 18, 2026, and the latest update filed on May 19, 2026, which signals active operational progress even though top-line results are not yet available.
For investors, this update extends Crispr Therapeutics beyond rare blood disorders into the vast cardiovascular space. Positive safety signals could support CRSP’s valuation, improve sentiment toward in vivo gene editing, and pressure rivals working on ANGPTL3 and other lipid targets, including RNA and antibody players.
The trial update confirms that the CTX310 program is active and ongoing, with more detailed information available on the ClinicalTrials portal.
To learn more about CRSP’s potential, visit the Crispr Therapeutics drug pipeline page.
